China's First Expert Consensus on Clinical Drug Treatment of Osteoarthritis Releases Key Products of Peak Pharmaceutical Yueyining Selected
Release time:
2021-07-21
News from our newspaper # February 10 , the Sports Medical Branch of the Chinese Medical Association and other units jointly released the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" in Hangzhou. This is the first time that the Chinese medical community has released osteoarthritis. Related expert consensus. Peak Pharmaceuticals' key product, Yue Yining (Aceclofenac Sustained Release Tablets), is included in the consensus list of therapeutic drugs.
"Expert Consensus on Clinical Drug Treatment of Osteoarthritis" was initiated by Chen Shiyi, winner of the "Chinese Medicine Award", director of the Sports Medicine Center of Fudan University, and director of the Orthopedic Arthroscopic Diagnosis and Treatment Technology Training Base of the Ministry of Health (Shanghai), the sports medicine branch of the Chinese medical association, the sports medicine group of the orthopaedic branch of the Chinese medical association, the arthroscopic society of the orthopaedic branch of the Chinese medical association and other units organized more than 30 relevant experts to jointly compile it, which took nearly 1 years to complete. the consensus is divided into 6 parts, and the full text is nearly 2 words. The experts participating in the discussion are distributed in 27 large-scale tertiary hospitals in 16 provinces (cities, autonomous regions) across the country, involving multiple disciplines such as orthopedics, sports medicine, pain, pharmacy, and evidence-based medicine. The formulation principles of rigorous, standardized, objective, practical, and economical, adhere to the guidance of evidence-based medicine, and fully integrate the current clinical practice of osteoarthritis in China, give more than 20 best clinical medication plan.
Yueyining (Aceclofenac Sustained Release Tablets), a key product of Jianfeng Pharmaceutical, has been recognized by experts and included in the consensus by virtue of its unique advantages. In the consensus, it is clearly pointed out that patients with osteoarthritis should choose the non-steroidal anti-inflammatory drug aceclofenac, which can promote the synthesis of cartilage matrix proteoglycan, and the slow-release dosage form can be preferred, which can better control the blood concentration and improve the compliance of patients with drugs.
According to introduction, osteoarthritis is prone to occur in middle-aged and elderly people with high incidence rate. More than 50% of knee pain people over 65 years old are osteoarthritis patients, and the prevalence rate of osteoarthritis in knee pain people over 75 years old exceeds 80% . With the promotion of national centralized procurement and disease diagnosis related sub-group (DRG) payment, the price of artificial joints has dropped significantly, and doctors and the business community are faced with the choice of surgery and medication, so the launch of this consensus is timely. According to the national standardization requirements for disease treatment, both conservative treatment and drug treatment need corresponding guiding principles, which are based on guidelines and expert consensus. On the basis of being included in the expert consensus this time, Jianfeng Pharmaceutical will make every effort to carry out the promotion of the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" to further guide the safe, effective, economical and standardized use of osteoarthritis treatment drugs in clinical practice. Highlight the clinical advantages of Yueyining and better expand the market of this product.
(Xu Yuting)
More information
Peak re-listed China's top 100 cement production capacity Daye peak won the "smart factory leader"
On July 11-12, the 2022 China Cement Industry Summit and TOP100 Award Ceremony organized by China Cement Network, an authoritative media of China's cement industry, was held in Hangzhou. Jianfeng Group once again ranked among the top 100 cement clinker production capacity in China.
2022
08-04
On the afternoon of July 12, the party Committee of the group company held a special meeting attended by party Committee members, senior and middle-level management backbones, heads of grass-roots party organizations and all party members of the group headquarters to learn and convey the spirit of the 15th party congress of the communist party of China in Zhejiang province.
2022
07-24
On the morning of July 1, more than 40 members of the group's party committee, party members of various branches of the group headquarters, and party members of subordinate enterprise branches went to the Shuanglong Hydropower Station, the Red Education Base of Jinhua City, to receive party spirit and revolutionary tradition education.
2022
07-14
Vocational skill level identification examination!
On June 16 and 18, the theoretical and practical examinations for the determination of professional skill level in the peak pharmaceutical sector were held successively in Jinxi pharmaceutical factory. The independent identification of vocational skill level includes three occupations (types of work): pharmaceutical preparation worker, chemical inspector and organic synthesis worker, basically covering the main posts in the pharmaceutical sector, with a total of 125 employees signing up for the identification.
2022
06-21
On June 16, the Jianfeng Pharmaceutical Quality Research and Development Party Branch and the Jinhua Vocational Skills Management Service Center Party Branch held a signing ceremony in Jinxi Factory to establish a party building alliance.
2022
06-21
Jinhua Mayor Xing Zhihong to Peak Research
On the afternoon of June 1, Jinhua Mayor Xing Zhihong, Wucheng District Party Committee Secretary Gao Feng, District Mayor Hu Yuxian, and heads of the Municipal Economic and Information Bureau, Development and Reform Bureau and other departments went to the group headquarters to discuss and exchange with the leaders of the group company to understand the development of the enterprise. Solicit opinions and suggestions from enterprises on government work. After understanding the current business situation of the peak, Xing Zhihong pointed out that focus, follow the right path, frontier, steady, is the peak to long-term prosperity of the magic weapon, must continue to adhere.
2022
06-13
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page